the kidney proximal tubules (renal Fanconi syndrome), leading to end-stage renal disease (ESRD) during childhood or early adolescence. Extrarenal manifestations include photophobia, retinopathy, endocrine dysfunction (hypothyroidism, endocrine pancreatic insufficiency, hypogonadism), peripheral myopathy, and central nervous system complications, which mostly develop during the second and third decades of life. 1, 2 In cystinosis patients, phagocytic cells, such as blood granulocytes and bone marrow and tissue macrophages, accumulate large amounts of cystine due to their phagocytic nature and their inability to process the phagocytized crystals.
3,4
The only available treatment for cystinosis is the cystine-depleting amino thiol cysteamine. However, this drug does not prevent progressive disease, but merely postpones the development of ESRD and extrarenal complications. 2 Moreover, cysteamine has numerous side effects that severely limit patient compliance.
5-7
Allogeneic hematopoietic stem cell transplantation (HSCT) has been established as a successful therapy for not only hereditary hematological disorders, but also for inborn errors of metabolism (IEMs), including many LSDs.
8,9
The first case of a successful bone marrow transplantation in a lysosomal disorder dates back to 1981 in a child affected by Hurler syndrome, or mucopolysaccharidosis t ype-1 (MPS1). 10 Since then, thousands of children have received HSCT as a therapeutic modality for LSDs, including other MPS syndromes, such as metachromatic leukodystrophy, Gaucher, Niemann-Pick A/B, α-mannosidosis, and many others. 8 However, the basic concept behind allogeneic HSCT in all these disorders is to replace the production of a deficient enzyme caused by the genetic defect of each LSD. The only IEM in which HSCT has been established as a therapy for a transporter deficiency is the peroxisomal disorder adrenoleukodystrophy (ALD). Allogeneic HSCT can reverse demyelination and progression of neurological symptoms when performed early in ALD, but the mechanism of action of HSCT is not clear, and the disease lacks an established animal model.
11,12
The Cherqui group showed that in the cystinosis (Ctns -/-) mouse model, HSCT significantly decreased cystine accumulation in different organs, preserved kidney function, and reversed extrarenal organ damage. [13] [14] [15] [16] They demonstrated the in situ differentiation of stem cells to tissue macrophages within target organs, which transferred cystinosin-bearing lysosomes to adjacent deficient cells via tunneling nanotubes. 17 The paracrine release of cellular microvesicles containing CTNS mRNA and protein has also been suggested as another potential mechanism of action. These animal studies provide the proof of concept for a beneficial effect of HSCT in hereditary diseases, where the defective proteins are endosomal or lysosomal membrane transporters, rather than enzymes. Here, we present a case of an adolescent male who had severe infantile cystinosis and who underwent HSCT.
| CASE REPORT
We treated a 16-year-old white boy, who was diagnosed with cystinosis at the age of 2.7 years and was started on cysteamine treatment at that time. DNA analysis demonstrated compound heterozygous mutations in the CTNS gene: 57-kb deletion and c.926dup (p.Ser310fs*55). At the age of 15, he developed signs of cysteamine toxicity, with cutaneous lesions at the level of lumbar vertebrae and bone lesions (cervical vertebrae, femur and tibia, overgrowth of rib cartilage) due to ongoing renal Fanconi syndrome associated with therapy-resistant copper deficiency. 7 Moreover, he had severe psychological and social problems due to cysteamine-induced halitosis.
5
The patient was subsequently referred to the bone marrow transplantation program at the University Hospitals Leuven. A family conference was held to discuss the potential risks and benefits of HSCT, Due to partial graft failure caused by a parvovirus B19 infection, a second HSC infusion from the same donor was administered 15 months after first HSCT, resulting in good reconstitution of the blood. The patient did not receive pretransplant conditioning or GVHD prophylaxis for the second HSC donation. Full donor chimerism (>95%) was also demonstrated in peripheral blood 140 days following the second donation. However, a severe therapy-resistant acute followed by chronic gastrointestinal, hepatic, and cutaneous GVHD developed, for which several immunosuppressive agents were used, including prednisolone, azathioprine, cyclosporine, ATG, and sirolimus. The severity scores for the liver, GI tract, and skin GVHD were grades 3, 3, and 2, respectively.
20
The kidney function gradually declined and the patient ultimately required chronic dialysis 18 months following initial HSCT. Unfortunately, 35 months after transplantation the patient developed a severe pneumonia due to a multiresistant Pseudomonas infection, and he succumbed to the disease.
To evaluate the long-term levels of the donor's mRNA in recipient tissues, we measured the percentage of expression of the wildtype (Wt) CTNS RNA in renal and liver cells 24 months after HSCT through reverse transcription, followed by next-generation sequencing (Figure 2A, B) . To obtain renal cells devoid of hematopoietic elements, we isolated tubular epithelial cells from the patient's urine as described previously by our group. 21 In addition, we measured solid organ (liver) Wt CTNS RNA in a liver specimen, which was obtained from a biopsy performed to assess the patient's GVHD. We also used The median number of crystals per macrophage was 7.8 (range 4-13). Tissues were fixed in glutaraldehyde, prepared as 1-µm-thick sections, and stained with toluidine blue. Images were acquired using a Leica DM2000 LED microscope, Leica DFC290 HD camera, and LAS acquisition software (Leica microsystems) at a magnification of 1000×. HSCT,
hematopoietic stem cell transplantation
We further investigated the protein expression of cystinosin by immunohistochemistry in different tissues pre-and post-HSCT using antibodies against cystinosin-LKG, which is an isoform of cystinosin,
resulting from an alternative splicing of exon 12 that removes the C-terminal GYDQL motif and replaces it with a string of 38 amino acids containing a ''SSLK'' domain that is strongly conserved among species. 23 At this time, no specific antibodies against conventional cystinosin isoform are available. Pretransplantation, the patient had no expression of cystinosin-LKG. This is due to 1 allele lacking the gene promotor needed for mRNA transcription (57-kb del) with the other allele having a frameshift mutation at AA-310 (p.Ser310fs*55), while the antiserum was directed against a cystinosin-LKG-specific sequence spanning amino acids 366-389. 
| DISCUSSION
There are 3 major phenotypes for cystinosis. Infantile nephropathic cystinosis is the most severe type, and constitutes >95% of cases.
This disease presents with renal impairment during the first year of life, and development of renal failure by the end of the first decade, Actual amplicon coverage by NGS was ≈100×. RNA isolation for renal tubular cells was performed using the RNeasy plus mini-kit (QIAGEN, Valencia, CA), while for the liver biopsy the TRIzol ® reagent (Invitrogen, Waltham, MA) was used. RNA isolated from tubular epithelial cells derived from the pretransplanted patient and a healthy individual was used as negative and positive controls for the Wt CTNS sequence, respectively. cDNA was synthesized with the SuperScript III RT kit (Invitrogen, Waltham, MA). Polymerase chain reaction was performed in duplicate for all cDNA samples for the propagation of exons 11 harboring the location of the point mutation of the patient, c.926dup using the primers (Fw: 5′ -CCACAGGCCTACATGAACTT-3′, Rv: 5′ -TCCACTGGTCGTTGTTGTAG-3′). NGS was performed using the MiSeq system platform (Illumina, San Diego, CA). The site of the point mutation (c.926dup) is marked by the red arrow. C, Immunohistochemical staining showing negative and positive controls for the cystinosin-LKG antibody. D, Immunohistochemical staining for cystinosin-LKG in different tissues of the patient before and 24 months (liver) or 30 months (stomach and gastroesophageal junction) after HSCT showing the expression in some epithelial cells. Immunostaining was according to the method of Taranta et al, 23 but antigen retrieval was performed at high pH9 (Dako). Images were acquired using a Zeiss AXIO Imager.A1 microscope, AxioCam MRc 5 camera, and AxioVision software (Zeiss). All images have a magnification of 400×, except stomach mucosa and liver tissue posttransplantation have a magnification of 630×. HSCT, hematopoietic stem cell transplantation along with multiorgan damage. Few cystinosis patients present with juvenile nephropathic cystinosis, which is a milder form of the disease that induces renal injury at a later age. Thirdly is the ocular type, which manifests only with photophobia due to corneal cystine crystal deposition, and spares other organs. 1, 2 Our patient presented with typical infantile nephropathic cystinosis; however, he was diagnosed and started cysteamine therapy relatively late, at 2.7 years of age. Cysteamine efficiently decreases cystine content in lysosomes through direct biochemical interaction with cystine. While it delays the natural course of the disease, it unfortunately is not able to prevent many of the pathogenic aspects of cystinosis, including the Fanconi syndrome and the subsequent renal failure.
1,2
Furthermore, our patient experienced significant side effects of cysteamine therapy, including bone involvement and halitosis, which severely impacted him psychosocially.
Allogeneic HSCT has contributed substantially to the improved survival and quality of life in children affected by different IEMs. Moreover, animal models of cystinosis provided the initial proof for the clinical benefits of HSCT. In the study by Syres et al, 13 organspecific cystine content was reduced in all organs tested in cystinotic mice treated with Wt bone marrow. These organs included brain (57% reduction), eye (71%), heart (82%), kidney (70%), liver (95%), muscle (66%), and spleen (87%). Yeagy et al 16 further confirmed the long-term protection of HSCT for the mouse kidney up to 15 months posttransplant and showed that high-level donor-cell engraftment was essential for efficient therapy. In subsequent studies, HSCT in the cystinotic mouse protected against both eye pathology and hypothyroidism.
14,15
Although our patient showed signs of clinical improvement of cystinosis (decreased polyuria and photophobia), he developed early signs of tacrolimus toxicity starting 4 weeks following the first HSCT. Similar cases with increased chances of nephrotoxicity and neurotoxicity may benefit from a calcineurin-free GVHD prophylaxis, such as the low-dose cyclophosphamide regimen. 24 Following the second HSC donation, our patient developed a severe form of GVHD, which did not respond to systemic corti- In conclusion, this is the first report describing allogeneic HSCT in a human patient with cystinosis, a lysosomal membrane transporter deficiency. This study broadens the spectrum of genetic diseases that may benefit from HSCT in clinical practice, and validates a novel mechanism of function of HSCs in hereditary metabolic disorders beyond simple compensation for enzyme deficiencies. However, this case history also highlights that the potential benefits of allogeneic HSCT should be carefully balanced against its risks and potential mortality. In our study, the expression of the Wt allele in the recipient's nonhematological epithelial cells with the subsequent decrease in cystine crystal accumulation, resolution of photophobia, and reduction in urinary output demonstrates that the CTNS donor-recipient gene and protein transfer does indeed occur, and that it can be functional in humans.
Similar to ALD, and other monogenic diseases, such as different forms of severe combined immune deficiency, thalassemia, and MPS, 25, 26 the feasibility and efficacy of autologous HSCT following ex vivo gene therapy should be explored in cystinosis in future studies to avoid the risks associated with allogeneic HSCT.
